A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer-Reference-Cited by-同舟云学术

A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer

Published:2022-01 Issue:1 Volume:22 Page:32-42
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Symonds Lynn,Jenkins Isaac,Linden Hannah M,Kurland Brenda,Gralow Julie R,Gadi Vijayakrishna (V.K.),Ellis Georgiana K,Wu Qian,Rodler Eve,Chalasani Pavani,Chai Xiaoyu,Riedel Jinny,SCCA Network Investigators ,Stopeck Alison,Brown-Glaberman Ursa,Specht Jennifer M

Funder

National Cancer Institute

Pfizer

Pfizer Foundation

National Comprehensive Cancer Network

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference60 articles.

1. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;Kuerer;J Clin Oncol,1999

2. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors. A study of preoperative treatment;Colleoni;Clin Cancer Res,2004